Menjugate

N. meningitidis Group C (Strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent disease caused by Neisseria meningitidis serogroup C in individuals at risk, such as infants, children, and adolescents.

GNH USA supplies Menjugate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Menjugate is a conjugate vaccine that targets meningococcal disease caused by serogroup C. - Infants: induction of protective antibodies against Neisseria meningitidis serogroup C. - Children and adolescents: booster protection to maintain immunity against serogroup C. - Adults at increased risk (e.g., travelers, outbreak settings): prevention of invasive meningococcal disease caused by serogroup C.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: transient headache post‑vaccination. - Fatigue: temporary tiredness. - Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with ascending weakness. - Seizures: uncommon neurologic event. - Severe hypotension: marked drop in blood pressure. - Persistent high fever: fever lasting more than 48 hours. - Severe local reaction: extensive necrosis or ulceration at the injection site.

Menjugate should be administered only after evaluating the individual's medical history. - Severe allergy: Do not vaccinate persons with a known severe hypersensitivity to any vaccine component. - Acute illness: Postpone vaccination in individuals with moderate or severe acute febrile illness. - Immunocompromised patients: Assess immune status as response may be reduced. - Blood product receipt: Delay vaccination for at least 3 months after receiving immunoglobulins or blood products. - Pregnancy and lactation: Use only if the potential benefit outweighs the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may interact with other agents that affect the immune system. Major Interactions (Avoid): - Live bacterial vaccines: avoid simultaneous administration to prevent interference with immune response. - Severe allergic reaction to a previous dose: contraindicated. Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may diminish vaccine efficacy; monitor antibody levels. - Antipyretics (e.g., acetaminophen, ibuprofen): can mask fever, a common post‑vaccination sign. - Blood products or immunoglobulins: may reduce immunogenicity if given within 3 months before or after vaccination.